Aldeyra Therapeutics announced positive top-line data from a Phase 2 clinical trial comparing reproxalap ophthalmic solution 0.25% (reproxalap) versus Novartis’ Xiidra (lifitegrast ophthalmic solution 5%), a common standard treatment in patients with dry eye disease. A statistically significant symptom improvement was reported in patients treated with reproxalap versus Xiidra. Aldeyra plans to present full data from the trial at an upcoming medical meeting.
The double-masked, crossover, single-center trial enrolled 56 dry eye disease patients. The trial evaluated the activity of reproxalap compared to Xiidra for two endpoints: ocular discomfort symptom score and ocular itching symptom score. A single dose of test article was administered to both eyes approximately 5 minutes prior to a dry eye chamber exposure lasting 45 minutes, during which humidity was maintained at low levels in a setting of regulated air flow, temperature, and visual tasking. Symptoms were assessed approximately 15 minutes prior to chamber entry, and every 5 minutes beginning 5 minutes after chamber entry.
Patient-reported ocular discomfort and itching were statistically lower with reproxalap than with X...
Note: If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).